Drugs / CD3/CD19 neg allogeneic BMT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03330795 | Dec 2017 → Mar 2024 | immunodeficiency disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD3/CD19 neg allogeneic BMT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03330795 ↗ |
| Action | Restore | “resulting in restoration of function in the immune system” NCT03330795 ↗ |
| Modality | Cell therapy | “hematopoietic stem cell transplantation (HSCT)” NCT03330795 ↗ |